📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Anlon Healthcare Announces 1:5 Stock Split; Face Value to Drop from ₹10 to ₹2
Anlon Healthcare Limited (AHCL) has initiated a postal ballot to seek shareholder approval for a 1:5 stock split. Under this proposal, each equity share with a face value of ₹10 will be sub-divided into five equity shares with a face value of ₹2 each. The total authorized share capital will remain unchanged at ₹55 crore, while the number of shares will increase to 27.5 crore. The e-voting process for shareholders is scheduled to take place between March 10 and April 08, 2026.
Key Highlights
Sub-division of 1 equity share of ₹10 face value into 5 equity shares of ₹2 face value
Total paid-up shares to increase from 5,31,51,500 to 26,57,57,500 post-split
Authorized share capital remains constant at ₹55,00,00,000
Remote e-voting period is set from March 10, 2026, to April 08, 2026
The split is intended to enhance liquidity and make shares more affordable for retail investors
💼 Action for Investors
Investors should monitor the record date for the split, which will be announced after shareholder approval. While the split increases the number of shares held, it does not change the fundamental value of the investment but may improve market liquidity.
Anlon Healthcare Approves 1:5 Stock Split and 1:1 Bonus Issue
Anlon Healthcare Limited has announced a significant restructuring of its share capital, starting with a 1:5 stock split that reduces the face value from Rs. 10 to Rs. 2. Following the split, the company will issue bonus shares in a 1:1 ratio to all eligible shareholders. To accommodate these changes, the authorized share capital is being doubled from Rs. 55 crore to Rs. 110 crore. These corporate actions are intended to enhance market liquidity and encourage wider participation from retail investors.
Key Highlights
Stock split of 1 equity share (FV Rs. 10) into 5 equity shares (FV Rs. 2) to improve liquidity
Bonus issue in the ratio of 1:1 (one new share for every one held) post-split adjustment
Authorized share capital increased from Rs. 55 crore to Rs. 110 crore to facilitate the issuance
Company has Rs. 147.08 crore in free reserves as of Dec 31, 2025, to support the Rs. 53.15 crore bonus capitalization
Expected completion of both corporate actions is within 2 months, by May 6, 2026
💼 Action for Investors
Investors should monitor the upcoming record date to be eligible for both the split and bonus shares. While these actions do not change the company's fundamentals, the increased liquidity and lower nominal price per share often attract higher retail trading volume.
Anlon Healthcare Extends Timeline for 56.67% Stake Acquisition in Bizotic Life Science
Anlon Healthcare Limited (AHCL) has announced an amendment to its Share Purchase Agreement (SPA) for the acquisition of a 56.67% stake in Bizotic Life Science Private Limited. The completion timeline for the transaction has been extended to April 2, 2026, which is 125 days from the original execution date of November 28, 2025. The company cited pending procedural requirements as the reason for this extension. This delay indicates that while the deal is still active, the final integration and control of the target company will take longer than initially anticipated.
Key Highlights
Acquisition involves a controlling 56.67% stake in Bizotic Life Science Private Limited.
Completion deadline extended to April 2, 2026, from the original schedule.
The new timeline allows for 125 days from the initial SPA date of November 28, 2025.
Extension is attributed to procedural requirements rather than financial or legal hurdles.
💼 Action for Investors
Investors should monitor the company's progress toward the new April 2 deadline to ensure the acquisition is finalized without further delays. The successful completion of this majority stake purchase is critical for AHCL's expansion plans.
Anlon Healthcare Q3 FY26 PAT at ₹5.15 Cr; Targets ₹380 Cr Revenue in FY27
Anlon Healthcare (AHCL) reported a strong Q3 FY26 with total income rising to ₹35.78 crore from ₹9.38 crore YoY, and a PAT of ₹5.15 crore. The company has provided an ambitious revenue guidance of ₹370-380 crore for FY27, driven by the integration of Apiqo Organic and the proposed acquisition of Bizotic Life Science. Management maintains a sustainable EBITDA margin target of 35% for domestic and 50% for regulated markets. A key focus remains on optimizing the balance sheet by reducing working capital days from 290 to 150-160 days by FY27.
Key Highlights
Q3 FY26 revenue surged to ₹35.78 crore vs ₹9.38 crore YoY, with EBITDA margins at 35.06%.
Management projects FY27 revenue at ₹370-380 crore, significantly higher than the FY26 guidance of ₹170-180 crore.
Total capacity across three facilities is estimated at 1,400-1,600 MTPA, with a further 800-1,000 MTPA Greenfield expansion planned.
Working capital cycle is being aggressively managed with a target to reduce receivable days from 290 to 150-160 days by next year.
CDMO segment is scaling with 3 molecules under development for global innovators, with one validation batch already dispatched.
💼 Action for Investors
Investors should monitor the successful integration of recent acquisitions and the actual reduction in receivable days to confirm operational efficiency. The high growth guidance and strong margin profile suggest a positive outlook for the company's expansion into regulated markets.
Anlon Healthcare to Quadruple Capacity to 1,600 MTPA via Acquisitions; Targets 30% Revenue CAGR
Anlon Healthcare is aggressively scaling its operations through the strategic acquisitions of Bizotic Lifescience and Apiqo Organics, aiming to increase total manufacturing capacity from 400 MTPA to 1,600 MTPA by FY26. The company has provided a growth guidance of 30% revenue CAGR over the next three years, supported by 21 global DMF filings and a significant shift in revenue mix toward pharmaceutical intermediates (71.8% in 9M FY26). Furthermore, the company is diversifying into high-growth sectors including e-waste management and lithium-ion battery recycling to drive long-term value.
Key Highlights
Total production capacity projected to reach 1,400-1,600 MTPA by FY26, a 4x increase from the current 400 MTPA.
Acquired 56.67% stake in Bizotic Lifescience for ₹3.79 crore and 67.48% in Apiqo Organics for ₹5.40 crore.
Management targets a 30% revenue CAGR over the next 3 years backed by a pipeline of 65 commercialized products.
Pharmaceutical Intermediates revenue contribution surged to 71.81% in 9M FY26 compared to 24.60% in 9M FY25.
Global regulatory footprint strengthened with 21 DMF filings and approvals from EDQM (Europe), ANVISA (Brazil), and NMPA (China).
💼 Action for Investors
Investors should monitor the successful integration of the two new acquisitions and the execution of the 30% CAGR growth guidance. The massive capacity expansion and entry into battery recycling offer significant upside potential, though operational efficiency during this rapid scaling phase will be key.
Anlon Healthcare Q3 FY26 PAT Turns Positive at ₹5.15 Cr; EBITDA Surges 20x YoY
Anlon Healthcare reported a massive turnaround in Q3 FY26, with total income growing 281% YoY to ₹35.78 crore. The company's EBITDA skyrocketed by over 2,000% to ₹12.54 crore, while PAT turned positive at ₹5.15 crore compared to a loss in the previous year. For the nine-month period, PAT grew by 365% to ₹18.02 crore with margins expanding significantly by 943 bps. Additionally, the company completed the acquisition of Apiqo Organics and is acquiring Bizotic Lifescience to boost capacity to 1,600 MTPA.
Key Highlights
Q3 FY26 Total Income surged 281.47% YoY to ₹35.78 crore.
EBITDA for Q3 grew 20x to ₹12.54 crore with PAT turning positive at ₹5.15 crore.
9M FY26 PAT increased by 365.61% YoY to ₹18.02 crore with a 14.85% margin.
Acquired 67.48% stake in Apiqo Organics for ₹5.40 crore to strengthen backward integration.
Management targets a 30% revenue CAGR over the next three years with capacity expansion to 1,600 MTPA.
💼 Action for Investors
Investors should view this as a strong growth signal given the massive margin expansion and strategic acquisitions. Monitor the integration of new subsidiaries and the achievement of the 30% CAGR guidance.
Anlon Healthcare Q3 PAT Drops 44.7% to ₹5.15 Cr; Appoints New CFO and Director
Anlon Healthcare Limited reported a significant decline in its Q3 FY26 performance, with revenue from operations falling 50.1% year-on-year to ₹35.58 crore. Net profit for the quarter also dropped sharply to ₹5.15 crore from ₹9.32 crore in the same period last year. However, on a nine-month basis, the company's profit after tax showed a substantial increase to ₹18.02 crore compared to ₹3.87 crore in the previous year. Alongside the results, the company announced the appointment of Mr. Naimish Dilipbhai Bhatt as the new CFO and Mr. Kishan Vinodkumar Raja as an Independent Director.
Key Highlights
Revenue from operations for Q3 FY26 fell 50.1% YoY to ₹35.58 crore from ₹71.36 crore.
Net profit for the quarter decreased by 44.7% YoY to ₹5.15 crore.
9M FY26 profit after tax stands at ₹18.02 crore, a significant jump from ₹3.87 crore in 9M FY25.
Mr. Naimish Dilipbhai Bhatt appointed as CFO effective February 09, 2026, succeeding Mr. Hitesh Makwana.
CA Kishan Vinodkumar Raja appointed as an Independent Director to strengthen board-level oversight.
💼 Action for Investors
Investors should monitor the reasons behind the sharp quarterly revenue and profit contraction despite the overall 9M growth. The leadership transition in the finance department warrants a watchful approach to see if operational efficiencies improve in the coming quarters.
Anlon Healthcare Q3 PAT Drops to ₹5.15 Cr; Announces CFO and Board Transitions
Anlon Healthcare Limited reported a sequential decline in its financial performance for the quarter ended December 31, 2025, with revenue from operations falling to ₹35.58 crore from ₹52.20 crore in the previous quarter. Net profit also saw a significant drop to ₹5.15 crore compared to ₹9.32 crore in Q2 FY26. Alongside the earnings, the company announced the resignation of CFO Hitesh Bhavanjibhai Makwana, who is replaced by Naimish Dilipbhai Bhatt. The board also saw the appointment of a new Independent Director, Kishan Vinodkumar Raja, following the resignation of Shailesh Kantilal Thakkar due to health reasons.
Key Highlights
Revenue from operations decreased by 31.8% sequentially to ₹35.58 crore in Q3 FY26.
Net Profit (PAT) for the quarter stood at ₹5.15 crore, down from ₹9.32 crore in the preceding quarter.
Total income for the nine-month period ended December 31, 2025, reached ₹121.32 crore with a PAT of ₹18.02 crore.
Appointment of Naimish Dilipbhai Bhatt as the new CFO, effective February 09, 2026.
Board reshuffle with the appointment of CA Kishan Vinodkumar Raja as an Independent Director.
💼 Action for Investors
Investors should exercise caution due to the sharp sequential decline in both top-line and bottom-line performance. Monitor the new CFO's ability to manage costs and stabilize margins in the upcoming quarters.
Anlon Healthcare Q3 PAT Falls 45% YoY to ₹5.15 Cr; Appoints New CFO and Director
Anlon Healthcare reported a weak third quarter for FY26, with revenue from operations dropping 50% YoY to ₹35.58 crore. Quarterly Net Profit (PAT) also saw a significant decline of 44.7% YoY, falling to ₹5.15 crore. However, the nine-month (9M) performance remains robust, with PAT surging to ₹18.02 crore compared to ₹3.87 crore in the previous year. Alongside results, the company announced a management overhaul, including the appointment of a new CFO and an Independent Director following resignations.
Key Highlights
Q3 Revenue from operations declined 50.1% YoY to ₹35.58 crore from ₹71.36 crore.
Net Profit (PAT) for the quarter fell 44.7% YoY to ₹5.15 crore compared to ₹9.32 crore in the previous year.
9M FY26 PAT shows a massive growth of 365% YoY, reaching ₹18.02 crore.
Appointment of Naimish Dilipbhai Bhatt as CFO, replacing Hitesh Bavanjibhai Makwana.
Kishan Vinodkumar Raja appointed as Independent Director following the resignation of Shailesh Kantilal Thakkar.
💼 Action for Investors
Investors should investigate the cause of the sharp Q3 revenue and profit contraction despite the strong 9M performance. The management transition in the finance department should be monitored for any impact on internal controls or strategic direction.
Anlon Healthcare Q3 FY26 Revenue Drops 50% YoY; New CFO Appointed
Anlon Healthcare reported a sharp decline in its Q3 FY26 performance, with revenue from operations falling 50% YoY to ₹35.58 crore. Net profit for the quarter also decreased significantly to ₹5.15 crore from ₹9.32 crore in the corresponding quarter last year. However, on a 9-month basis, the company showed resilience with a net profit of ₹18.02 crore compared to just ₹3.87 crore in the previous year. The company also announced a management shuffle, appointing Mr. Naimish Dilipbhai Bhatt as the new CFO.
Key Highlights
Quarterly revenue from operations fell 50.1% YoY to ₹35.58 crore in Q3 FY26
Net profit for the quarter declined 44.7% YoY to ₹5.15 crore
9-month cumulative net profit rose significantly to ₹18.02 crore from ₹3.87 crore YoY
Appointment of Mr. Naimish Dilipbhai Bhatt as CFO effective February 09, 2026
Mr. Kishan Vinodkumar Raja appointed as an Additional Non-Executive Independent Director
💼 Action for Investors
Investors should investigate the cause of the sharp 50% quarterly revenue drop despite the strong 9-month profit growth. Monitor the impact of the new CFO on financial reporting and internal controls in the coming quarters.
Anlon Healthcare Q3 PAT Hits ₹5.15 Cr Amid 50% Revenue Drop; New CFO Appointed
Anlon Healthcare reported a significant decline in Q3 FY26 revenue, which fell to ₹35.58 crore from ₹71.36 crore in the same period last year. Despite the top-line contraction, the company achieved a turnaround in profitability, posting a net profit of ₹5.15 crore compared to a loss of ₹2.49 crore in Q3 FY25. For the nine-month period ending December 2025, PAT surged to ₹18.02 crore from ₹3.87 crore year-on-year. The company also announced a management shuffle, appointing Mr. Naimish Dilipbhai Bhatt as the new CFO following the resignation of Mr. Hitesh Bavanjibhai Makwana.
Key Highlights
Revenue from operations for Q3 FY26 declined 50% YoY to ₹35.58 crore from ₹71.36 crore.
Net Profit (PAT) for the quarter stood at ₹5.15 crore, recovering from a net loss of ₹2.49 crore in Q3 FY25.
9-month PAT showed robust growth, reaching ₹18.02 crore compared to ₹3.87 crore in the previous year.
Mr. Naimish Dilipbhai Bhatt appointed as CFO, bringing over 18 years of experience in financial reporting and compliance.
Board changes include the appointment of CA Kishan Vinodkumar Raja as an Independent Director and the resignation of Mr. Shailesh Kantilal Thakkar.
💼 Action for Investors
Investors should closely monitor the reasons behind the sharp 50% decline in quarterly revenue despite the improved profit margins. The transition in the CFO role and board composition requires observation to ensure operational stability and a return to top-line growth.
Anlon Healthcare Q3 PAT at ₹5.15 Cr; Appoints New CFO and Independent Director
Anlon Healthcare reported a standalone Profit After Tax (PAT) of ₹5.15 crore for the quarter ended December 31, 2025, a significant recovery from a loss of ₹2.48 crore in the same period last year. However, revenue from operations saw a sharp decline of 50% year-on-year, falling to ₹35.57 crore from ₹71.35 crore. For the nine-month period, the company showed robust performance with PAT surging to ₹18.01 crore compared to ₹3.87 crore in the previous year. The company also announced a management transition, appointing Mr. Naimish Dilipbhai Bhatt as the new CFO following the resignation of Mr. Hitesh Makwana.
Key Highlights
Q3 FY26 PAT stood at ₹5.15 crore, turning around from a loss of ₹2.48 crore in Q3 FY25.
Revenue from operations for the quarter dropped 50% YoY to ₹35.57 crore.
9M FY26 PAT increased significantly to ₹18.01 crore from ₹3.87 crore in 9M FY25.
Total expenses for Q3 FY26 were drastically reduced to ₹25.16 crore from ₹71.28 crore in the year-ago quarter.
Management changes include a new CFO and the appointment of Mr. Kishan Vinodkumar Raja as an Independent Director.
💼 Action for Investors
Investors should investigate the cause of the 50% drop in quarterly revenue despite the improved profitability. Monitor the impact of the new CFO on financial reporting and internal controls.
Anlon Healthcare Q3 Revenue Drops 50% YoY; 9M PAT Surges to ₹18.02 Cr
Anlon Healthcare Limited reported a significant decline in its quarterly performance for Q3 FY26, with revenue from operations falling 50% YoY to ₹35.58 crore. Despite the quarterly slump, the nine-month (9M) performance shows a massive surge in Profit After Tax (PAT) to ₹18.02 crore, up from ₹3.87 crore in the previous year, largely due to better cost management over the full period. The company also announced a leadership transition, appointing Naimish Dilipbhai Bhatt as the new CFO and Kishan Vinodkumar Raja as an Independent Director. The sharp quarterly revenue contraction remains a point of concern for short-term growth momentum.
Key Highlights
Q3 FY26 Revenue from operations fell 50.1% YoY to ₹35.58 crore from ₹71.36 crore.
Quarterly Net Profit (PAT) declined to ₹5.15 crore in Q3 FY26 compared to ₹9.32 crore in Q3 FY25.
9M FY26 PAT increased significantly to ₹18.02 crore from ₹3.87 crore in the corresponding nine-month period last year.
Naimish Dilipbhai Bhatt appointed as Chief Financial Officer (CFO) effective February 09, 2026.
Kishan Vinodkumar Raja, a Chartered Accountant with 14 years of experience, appointed as an Independent Director.
💼 Action for Investors
Investors should seek clarity on why Q3 revenues halved despite the strong cumulative 9M profit growth. The management transition in the finance department should be monitored to ensure continued stability in financial reporting.
Anlon Healthcare Q3 PAT Drops 44.7% YoY to ₹5.15 Cr; CFO and Board Changes Announced
Anlon Healthcare reported a weak performance for the quarter ended December 31, 2025, with revenue from operations falling 50% year-on-year to ₹35.58 crore. Net profit for the quarter also saw a significant decline of 44.7%, reaching ₹5.15 crore compared to ₹9.32 crore in the same period last year. While nine-month revenue showed growth at ₹121.08 crore, the overall profitability for the nine-month period remains lower than the previous year. The company also announced a transition in leadership with the appointment of Mr. Naimish Dilipbhai Bhatt as the new CFO.
Key Highlights
Revenue from operations for Q3 FY26 fell 50.1% YoY to ₹35.58 crore from ₹71.36 crore.
Net Profit for the quarter declined 44.7% YoY to ₹5.15 crore against ₹9.32 crore in Q3 FY25.
9-month revenue for FY26 grew to ₹121.08 crore compared to ₹93.57 crore in the previous year.
Mr. Naimish Dilipbhai Bhatt appointed as CFO following the resignation of Mr. Hitesh Bavanjibhai Makwana.
Mr. Kishan Vinodkumar Raja appointed as an Independent Director, while Mr. Shailesh Kantilal Thakkar resigned due to health reasons.
💼 Action for Investors
Investors should exercise caution given the sharp quarterly contraction in both revenue and profit. It is important to monitor whether the new CFO can address the volatility in financial performance and improve margins in upcoming quarters.
Anlon Healthcare Commences Exports to Italy and Germany Following India-EU Trade Pact
Anlon Healthcare Limited (AHCL) has announced the commencement of exports for one of its key products to Italy and Germany. This strategic move follows the signing of a trade agreement between the Government of India and the European Union (EU) to enhance bilateral trade. The company expects this expansion into high-value regulated markets to have a positive impact on its operational performance. This development validates the company's product quality standards for the European market.
Key Highlights
Successful export of a key product to Italy and Germany within the European Union
Strategic alignment with the newly signed India-EU trade agreement
Anticipated positive impact on company operations and international revenue streams
Entry into highly regulated European markets which typically offer higher margins
💼 Action for Investors
Investors should monitor the revenue contribution from these new EU markets in upcoming quarterly reports. The ability to export to Italy and Germany is a positive indicator of the company's compliance with international quality standards.
Anlon Healthcare Completes Acquisition of 67.48% Stake in Apiqo Organics
Anlon Healthcare Limited (AHCL) has officially completed the acquisition of a 67.48% equity stake in Apiqo Organics Private Limited as of January 9, 2026. This transaction follows the Share Purchase Agreement executed on December 2, 2025, and marks the successful transition of the target company into a subsidiary. Apiqo Organics, formerly known as Apple Life Science, will now be consolidated into AHCL's financial statements. This strategic move is intended to expand the company's operational footprint and market presence.
Key Highlights
Successfully acquired 67.48% equity shareholding in Apiqo Organics Private Limited
Apiqo Organics has officially become a subsidiary of Anlon Healthcare Limited
The acquisition was finalized on January 9, 2026, following the SPA dated December 2, 2025
Target company was previously a partnership firm operating under the name M/s Apple Life Science
💼 Action for Investors
Investors should monitor the upcoming quarterly results to assess the revenue and margin contribution from the newly acquired subsidiary. This acquisition indicates a growth-oriented strategy that could enhance long-term shareholder value.
Anlon Healthcare Shareholders Approve Variation in IPO Objects for Inorganic Growth
Anlon Healthcare Limited (AHCL) has received overwhelming shareholder approval to modify the utilization of its Initial Public Offering (IPO) proceeds. The special resolution, passed with 99.99% of the votes in favor, allows the company to redirect funds toward proposed expansion through inorganic growth and further facility upgradation. A total of 30.45 million votes were cast, representing approximately 57.29% of the total paid-up equity capital. This strategic shift indicates management's intent to pursue acquisitions or partnerships to accelerate business scaling.
Key Highlights
Special resolution passed with 99.99% majority (30,448,093 votes in favor vs 46 against)
Total voter turnout recorded at 57.29% of the total paid-up equity capital of 53,151,500 shares
IPO proceeds redirected toward inorganic growth opportunities and facility upgradation
The remote e-voting process concluded on January 07, 2026, with 11,732 shareholders on record
The change in capital allocation was supported by 100% of the promoter group votes polled
💼 Action for Investors
Investors should monitor the company's future announcements regarding potential acquisitions or partnerships, as this change signals an aggressive inorganic growth strategy. The high level of shareholder consensus reflects strong confidence in management's revised capital allocation plan.
Anlon Healthcare to Vary IPO Objects for Inorganic Growth via Postal Ballot
Anlon Healthcare Limited (AHCL) has issued a postal ballot notice seeking shareholder approval to modify the utilization of its IPO proceeds. The company proposes to redirect funds originally earmarked for specific capital expenditures, as per its August 30, 2025 prospectus, toward inorganic growth opportunities and further facility upgradation. Shareholders can cast their votes electronically until January 07, 2026, with the final results expected by January 09, 2026. This strategic shift suggests the company is looking to accelerate expansion through acquisitions shortly after its public listing.
Key Highlights
Proposed Special Resolution to vary the objects of the IPO proceeds from the August 30, 2025 prospectus.
Funds to be redirected toward inorganic growth (acquisitions) and further facility upgradation.
Remote e-voting period is open until January 07, 2026, at 5:00 p.m. IST.
The company has appointed Mr. Keyur Ghelani as the Scrutinizer for the voting process.
Results of the postal ballot will be announced on or before Friday, January 09, 2026.
💼 Action for Investors
Investors should monitor the company's specific plans for inorganic growth to ensure capital is being deployed into value-accretive acquisitions. A shift in strategy so soon after an IPO requires careful observation of management's execution and the quality of potential targets.
AHCL acquires 67.48% stake in Apiqo Organics for ₹5,40,06,960
Anlon Healthcare Limited (AHCL) has entered into a Share Purchase Agreement (SPA) to acquire a 67.48% shareholding in Apiqo Organics Private Limited. The acquisition cost is ₹5,40,06,960 for 55,33,500 equity shares priced at ₹9.76 each. This strategic move aims to enhance AHCL's vertical integration and secure the supply of high-quality pharmaceutical intermediates. Apiqo Organics reported a turnover of ₹3,887.41 Lakh as of October 31, 2025.
Key Highlights
Acquisition of 67.48% shareholding in Apiqo Organics Private Limited
Acquisition cost of ₹5,40,06,960
55,33,500 equity shares acquired at ₹9.76 per share
Apiqo Organics turnover of ₹3,887.41 Lakh as of 31.10.2025
Expected completion of acquisition within 3 months
💼 Action for Investors
This acquisition is expected to strengthen AHCL's position in the pharmaceutical industry. Investors should monitor the integration of Apiqo Organics and its impact on AHCL's future earnings.